Luo FR - Search Results

1

Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.

Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E, Huang F. Wang XD, et al. Among authors: luo fr. Genome Biol. 2007;8(11):R255. doi: 10.1186/gb-2007-8-11-r255. Genome Biol. 2007. PMID: 18047674 Free PMC article.

2

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.

Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Rose WC, Kramer RA, Wild R, Lee FY. Luo FR, et al. Cancer Chemother Pharmacol. 2005 Nov;56(5):455-64. doi: 10.1007/s00280-005-1022-3. Epub 2005 Jun 10. Cancer Chemother Pharmacol. 2005. PMID: 15947929

3

Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.

Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Wong TW, Kramer RA, Wild R, Lee FY. Luo FR, et al. Clin Cancer Res. 2005 Aug 1;11(15):5558-65. doi: 10.1158/1078-0432.CCR-05-0368. Clin Cancer Res. 2005. PMID: 16061873

4

Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.

Wong TW, Lee FY, Yu C, Luo FR, Oppenheimer S, Zhang H, Smykla RA, Mastalerz H, Fink BE, Hunt JT, Gavai AV, Vite GD. Wong TW, et al. Among authors: luo fr. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6186-93. doi: 10.1158/1078-0432.CCR-06-0642. Clin Cancer Res. 2006. PMID: 17062696

5

Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.

Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K, Flefleh C, Castaneda S, Inigo I, Kan D, Wen ML, Kramer R, Blackwood-Chirchir A, Lee FY. Luo FR, et al. Clin Cancer Res. 2006 Dec 1;12(23):7180-6. doi: 10.1158/1078-0432.CCR-06-1112. Clin Cancer Res. 2006. PMID: 17145844

6

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.

Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY. Luo FR, et al. Cancer Chemother Pharmacol. 2008 Nov;62(6):1065-74. doi: 10.1007/s00280-008-0699-5. Epub 2008 Feb 27. Cancer Chemother Pharmacol. 2008. PMID: 18301894 Free article.

7

Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.

Eley T, Luo FR, Agrawal S, Sanil A, Manning J, Li T, Blackwood-Chirchir A, Bertz R. Eley T, et al. Among authors: luo fr. J Clin Pharmacol. 2009 Jun;49(6):700-9. doi: 10.1177/0091270009333854. Epub 2009 Apr 24. J Clin Pharmacol. 2009. PMID: 19395585 Clinical Trial.

8

Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.

Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.

9

Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.

Wild R, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Luo FR, Camuso A, McGlinchey K, Rose WC. Wild R, et al. Among authors: luo fr. Mol Cancer Ther. 2006 Jan;5(1):104-13. doi: 10.1158/1535-7163.MCT-05-0259. Mol Cancer Ther. 2006. PMID: 16432168

10

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.

Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA. Johnson FM, et al. Among authors: luo fr. Cancer. 2010 Mar 15;116(6):1582-91. doi: 10.1002/cncr.24927. Cancer. 2010. PMID: 20108303 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page